BCM
CHRS icon

Bayesian Capital Management’s Coherus Oncology CHRS Stock Holding History

Bayesian Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,100
Closed -$19.5K – 653
2024
Q4 		$19.5K Buy
+14,100
New +$15.8K ﹤0.01% 644
2024
Q2 		– Sell
-23,559
Closed -$56.3K – 785
2024
Q1 		$56.3K Buy
+23,559
New +$58K 0.01% 732
2023
Q1 		– Sell
-23,800
Closed -$188K – 823
2022
Q4 		$188K Buy
+23,800
New +$183K 0.03% 611
2020
Q1 		– Sell
-10,536
Closed -$190K – 796
2019
Q4 		$190K Buy
+10,536
New +$194K 0.03% 540
2018
Q2 		– Sell
-19,600
Closed -$217K – 611
2018
Q1 		$217K Buy
+19,600
New +$214K 0.06% 480

Other funds holding CHRS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Bayesian Capital Management's CHRS Position: Q1 2025 in Review

Bayesian Capital Management sold out of Coherus Oncology (CHRS) in Q1 2025, closing a stake of 14,100 shares — an estimated $19.5K sold.

Bayesian Capital Management first reported a position in CHRS in Q1 2018 and held it in 5 quarters. The position peaked at $217K in Q1 2018. 117 funds tracked by Wall St. Rank hold CHRS as of Q1 2025.

  • Bayesian Capital Management reported no remaining Coherus Oncology position as of Q1 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 14,100 Coherus Oncology shares in Q1 2025, an estimated $19.5K.
  • Bayesian Capital Management first reported a position in Coherus Oncology in Q1 2018 and held it in 5 quarters.
  • Bayesian Capital Management's Coherus Oncology position peaked at $217K in Q1 2018.
  • 117 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2025.

Based on Bayesian Capital Management's 13F filing for Q1 2025, filed 15 May 2025.